Discounted Cash Flow (DCF) Analysis Levered
Matinas BioPharma Holdings, Inc. (MTNB)
$0.134
+0.00 (+3.08%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.12 | 0.09 | 0.16 | 0.03 | 3.19 | 78.39 | 1,927.77 | 47,405.03 | 1,165,716.87 | 28,665,648.92 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -10.32 | -14.09 | -17.37 | -15.22 | -19.16 | -12,781.12 | -314,295.09 | -7,728,697.21 | -190,053,112.98 | -4,673,515,442.82 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.54 | -0.41 | -0.01 | -0.26 | -0.89 | -268.26 | -6,596.68 | -162,216.10 | -3,988,987.17 | -98,091,490.57 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -10.86 | -14.50 | -17.37 | -15.48 | -20.05 | -13,049.38 | -320,891.77 | -7,890,913.30 | -194,042,100.15 | -4,771,606,933.39 |
Weighted Average Cost Of Capital
| Share price | $ 0.134 |
|---|---|
| Beta | 2.022 |
| Diluted Shares Outstanding | 216.81 |
| Cost of Debt | |
| Tax Rate | 38.01 |
| After-tax Cost of Debt | -54.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 13.984 |
| Total Debt | 4.12 |
| Total Equity | 29.05 |
| Total Capital | 33.18 |
| Debt Weighting | 12.43 |
| Equity Weighting | 87.57 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.12 | 0.09 | 0.16 | 0.03 | 3.19 | 78.39 | 1,927.77 | 47,405.03 | 1,165,716.87 | 28,665,648.92 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.32 | -14.09 | -17.37 | -15.22 | -19.16 | -12,781.12 | -314,295.09 | -7,728,697.21 | -190,053,112.98 | -4,673,515,442.82 |
| Capital Expenditure | -0.54 | -0.41 | -0.01 | -0.26 | -0.89 | -268.26 | -6,596.68 | -162,216.10 | -3,988,987.17 | -98,091,490.57 |
| Free Cash Flow | -10.86 | -14.50 | -17.37 | -15.48 | -20.05 | -13,049.38 | -320,891.77 | -7,890,913.30 | -194,042,100.15 | -4,771,606,933.39 |
| WACC | ||||||||||
| PV LFCF | -12,365.56 | -288,142.09 | -6,714,280.14 | -156,455,996.80 | -3,645,733,931 | |||||
| SUM PV LFCF | -3,809,204,715.59 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 5.53 |
| Free cash flow (t + 1) | -4,867,039,072.06 |
| Terminal Value | -137,876,460,964.84 |
| Present Value of Terminal Value | -105,344,153,247.01 |
Intrinsic Value
| Enterprise Value | -109,153,357,962.61 |
|---|---|
| Net Debt | -2.71 |
| Equity Value | -109,153,357,959.90 |
| Shares Outstanding | 216.81 |
| Equity Value Per Share | -503,448,334.94 |